Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

Shelley Wood

November 14, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Conference News ACC 2023

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

Yael L. Maxwell

March 13, 2023

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

Michael O'Riordan

June 13, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Tailored Alerts Up High-Intensity Statin Prescribing: PCDS Statin

A Simple Nudge Moves the Needle on Statin Prescribing

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

TCTMD’s Top 10 Most Popular Stories for November 2018

Among African Americans in Need of LDL Lowering: Less Statin Use, More Distrust of Doctors

TCTMD’s Top 10 Most Popular Stories for May 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

Alirocumab to Remain On Market While Companies Clash Over Patents

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content